Clarity Pharmaceuticals (CU6) H2 2024 earnings summary

Executive summary

• Achieved significant clinical milestones in FY2023-2024, advancing three key products (SAR-bisPSMA, SAR-Bombesin, SARTATE) across seven clinical trials, including two Phase III registrational trials for prostate cancer diagnostics and multiple Phase I/II trials for therapy and diagnostics in prostate and neuroblastoma cancers.

• Fast Track Designation granted by the U.S. FDA for 64Cu-SAR-bisPSMA, expediting regulatory review for prostate cancer imaging.

• Expanded manufacturing and supply chain with new agreements for copper-64, copper-67, and actinium-225, ensuring scalable, reliable, and environmentally sustainable production.

• Raised $121 million in equity, strengthening cash reserves to $136.5 million, providing runway into 2026.

Financial highlights

• Reported a net loss of $42.3 million for FY2024, compared to a $24.6 million loss in FY2023, driven by a $10.5 million increase in R&D expenditure to $42.0 million.

• Liquid assets increased to $136.5 million (2023: $65.0 million), with net assets rising to $146.3 million (2023: $69.1 million).

• No commercial revenue; income derived from finance income ($2.8 million) and R&D tax incentive ($11.5 million).

• Successfully completed a $121 million capital raise in April 2024.

Outlook and guidance

• Strong cash position supports continued clinical development and expansion of the product pipeline through at least 2026.

• Focus remains on progressing Phase III trials for prostate cancer diagnostics and advancing therapeutic programs for prostate cancer and neuroblastoma.

• Ongoing expansion of manufacturing and supply agreements to support future commercial launches.